Organoid Culture Patents: Who Leads, Where the Gaps Are 2026
- 17.5% concentration at the top. The five leading assignees hold 337 of 1,928 records in scope, but the remaining 91.6% is spread across a long tail of single- and few-filing entrants.
- Filing has cooled from its 2019 peak. 181 records published in 2019 against 86 in 2024, a -32% swing from 2021's 127 — a real pullback, not a data artefact, since 2024 is the last complete year before publication lag distorts the count.
- Claim density sits on medium and matrix, not on hardware. C12N (87.3% of records) and A61K (36.7%) dominate; bioreactor apparatus under C12M covers only 8.1%, leaving culture hardware comparatively open.
Filing growth compares 2021 (127 records) with 2024 (86) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,928 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families where organoid culture, intestinal organoid or differentiation protocol claims intersect with practical production problems: matrix dependency, batch variability, maturation state, size heterogeneity, medium composition and long-term culture. That intersection is deliberate — it isolates the applied, scale-up layer of organoid science rather than every stem-cell or tissue-engineering filing that happens to mention an organoid.
Coverage runs from 2015-01-01 to the 2026-07-31 cut-off, spanning 1,928 published records. Because publication typically lags filing by around 18 months, the counts for 2025 and 2026 will keep rising as more applications publish; treat the most recent two years as a floor, not a ceiling.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,928-record set: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Filings rose from 97 in 2017 to a peak of 181 in 2019, then eased. The 2021-to-2024 span shows a -32% move (127 to 86) — the clearest complete-year comparison the data supports, since 2025 and 2026 are still filling in under normal publication lag.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) touches 87.3% of the 1,928 records, with A61K (medicinal preparations) at 36.7% and G01N (material analysis and testing) at 16.5%. Records can carry more than one class, so these shares overlap rather than sum to 100%.
Shares are the percentage of the 1,928 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organoid Culture and Differentiation with Eureka
This page is one run against one query. Ask Eureka your own question about organoid culture and differentiation and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited prior art and a recent representative filing
US20250075187A1 — Medium composition for preparation of intestinal organoid
Filed by ORGANOIDSCIENCES LTD. and published 2025-03-06, this filing claims a medium composition for preparing intestinal organoids, along with the preparation method and the resulting organoid. The stated effect is promoting organoid proliferation while maintaining stemness, aimed at producing large quantities of consistent-quality intestinal organoids for use in treating or preventing intestine-associated conditions.Representative of a filing pattern common in this dataset: medium-composition claims paired with a use claim on the resulting organoid, which extends the practical reach of a formulation patent beyond the medium itself.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050054098A1 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same | 356 |
| 2 | US20050153442A1 | Adipose-derived stem cells and lattices | 261 |
| 3 | US20030161817A1 | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof | 239 |
| 4 | US20070036767A1 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same | 195 |
| 5 | US7510873B2 | Postpartum cells isolated from umbilical cord tissue, and methods of making and using the same | 192 |
| 6 | US20060223177A1 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same | 171 |
| 7 | US20050076396A1 | Adipose-derived stem cells and lattices | 163 |
| 8 | US20070014771A1 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same | 161 |
| 9 | US20070009494A1 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same | 157 |
| 10 | US20070122905A1 | PDX1-expressing dorsal and ventral foregut endoderm | 151 |
Citation counts favour older filings simply because they have had longer to accumulate them — read them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three read-outs from the numbers above, framed around where to file, who to watch and what is still open.
The top is real but shallow
The five leading assignees combined hold 337 of 1,928 records — meaningful concentration, but it leaves the large majority of the field to single- and few-filing entrants. That pattern favours licensing and cross-filing moves over trying to out-file an established leader head-on.
Volume has pulled back from its 2019 high
Filings peaked at 181 in 2019 and the last complete comparison window shows a genuine decline, from 127 in 2021 to 86 in 2024. Recent-year momentum by assignee shows several previously active filers at zero in the latest year, consistent with a cooling rather than a temporary dip.
Medium and biology are crowded; apparatus is not
C12N and A61K together dominate claim language around genetic engineering and medicinal preparations, while C12M — the bioreactor and culture-apparatus class — covers only 8.1% of records. Hardware and process-engineering claims sit on comparatively thinner prior art than formulation claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoid culture and differentiation, with the prior art for and against each one.
Who is filing, and where the claim space is still open
The ranked list runs to 100 companies drawn from academic medical centres, national research agencies and specialist organoid start-ups — not a single dominant industrial filer.
Academic and public-research filers set the pace
The leading assignee's 87 records sit well ahead of fifth place at 60, but the gap to the tenth-ranked filer (39) is comparatively gentle — this is a field led by cancer centres, national research agencies and university tech-transfer offices rather than a single commercial incumbent.
Strategic pairs cluster around a handful of institutions
Co-assignee activity is concentrated in a small number of strong pairs rather than a broad collaboration network — ten pairs in total, with the strongest running well above the others. That pattern points to specific institutional partnerships rather than an open pre-competitive consortium.
Several early leaders have gone quiet
More than one previously active assignee shows zero filings in the latest tracked year, including filers that posted double-digit totals earlier in the window. That is consistent with the broader -32% pullback and suggests some of today's top-ranked names are coasting on legacy filings rather than actively expanding.
| Assignee | Recent year | YoY |
|---|---|---|
| Agency for Science, Technology and Research (A*STAR) | 1 | — |
| Memorial Sloan Kettering Cancer Center | 0 | — |
| University Health Network | 0 | — |
| Royal Netherlands Academy of Arts and Sciences | 0 | -100% |
| BioLamina | 0 | -100% |
| Genesis Technology Limited | 0 | — |
| ViaCyte, Inc. | 0 | — |
| The Board of Trustees of the Leland Stanford Junior University | 0 | -100% |
Where to take this analysis
The figures above frame the landscape; the next layer of work is claim-level and assignee-level diligence specific to what you plan to file or license.
Run a freedom-to-operate check on medium composition
With C12N and A61K covering the large majority of records, a targeted claim-chart comparison against the leading assignees' medium and differentiation-protocol patents is the highest-value next step before drafting new formulation claims.
Explore in Eureka →Track the quiet leaders for renewed activity
Several top-10 assignees show zero filings in the latest year. Set up ongoing monitoring so a resumption of filing activity or a new assignment doesn't arrive as a surprise.
Set up monitoring in Eureka →Scope the apparatus white space
C12M's 8.1% share suggests bioreactor and long-term-culture hardware claims are comparatively open. A deeper prior-art pull on that subclass alone would clarify how much room remains.
Pull the C12M subset in Eureka →Common questions on this landscape
The leading assignee in this dataset holds 87 of the 1,928 records in scope, with the fifth-ranked filer at 60 and the tenth at 39. The top five combined account for 17.5% of all records, which is real concentration but still leaves the majority of filings spread across a long tail of academic centres, national research agencies and smaller biotech entrants. No single commercial company dominates the way you'd see in some other life-science patent fields.
Filing peaked in 2019 at 181 records and has since pulled back; the clearest complete-year comparison shows a -32% change from 127 records in 2021 to 86 in 2024. Because publication lags filing by roughly 18 months, the 2025-2026 counts in any dataset will look artificially low and should not be read as continued decline. Based on the last fully-settled years, though, the field has genuinely cooled from its 2019 high.
US20250075187A1, filed by ORGANOIDSCIENCES LTD. and published in March 2025, claims a specific medium composition for preparing intestinal organoids, the method of culturing with that medium, and the intestinal organoid produced by that method. That three-layer structure — composition, method, product — means a competitor's medium would need to differ materially in formulation to avoid the claims, and simply changing the downstream use case doesn't clear the product claim if the underlying medium is substantially the same. It is representative of a broader pattern in this dataset where medium-composition patents extend their reach through paired method and product claims.
The heaviest claim density sits in C12N (87.3% of records) and A61K (36.7%), covering genetic-engineering methods and medicinal preparations. Bioreactor and culture-apparatus claims under C12M cover only 8.1% of records, and specific sub-areas like automated size-heterogeneity sorting, batch-to-batch matrix substitutes and maturation-state quality assays show comparatively light coverage. That makes apparatus and quality-control claims a more promising area to explore than another medium-formulation filing.
The United States leads with 507 filings, followed by Europe via the EPO at 363 and the WIPO PCT route at 331. Australia (145), Canada (112) and Israel (71) follow at a lower volume. That spread suggests organoid culture and differentiation IP is being actively protected across all three major global filing systems rather than concentrated in one jurisdiction, which matters for freedom-to-operate planning if you're commercializing outside the US.
Research Organoid Culture and Differentiation in depth with Eureka
Go past this page: query the whole organoid culture and differentiation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.